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Objectives: We hypothesized that the CD40/CD40 ligand (CD40L) system is up-regulated in the
metabolic syndrome (MS) andmodulated by adiponectin (AN). The objectives were: 1) to compare
plasma andmonocyte CD40L in patients with MS and controls and its association with clinical and
biochemical parameters, 2) to investigate platelets as a source of soluble CD40L (sCD40L), and 3)
to analyze the effects of AN on CD40/CD40L.
Methods:Plasma sCD40LandANweremeasured in246 controls and128patientswithMSbyELISA.
Monocyte CD40/CD40L expression and platelet CD40L content and release were compared in
patients with MS and controls. Monocytes and endothelial cells were cultured with AN and CD40/
CD40L expression determined by real-time RT-PCR and Western blotting.
Results:PatientswithMShadhigher sCD40Land lowerAN levels than controls (0.890.1 vs.0.76
0.07 ng/ml and 10.10  0.65 vs. 12.99  0.80 g/ml, P  0.05). Monocyte CD40/CD40L expression
was higher (P  0.05) in patients than controls (CD40: 1.31  0.31 vs. 0.80  0.14 arbitrary units;
CD40L: 1.24 0.85 vs. 0.43 0.14 pg/g protein). No differences were observed on CD40L content
between restingplatelets frompatientswithMSandcontrols (7.73.5 vs.7.22.2pg/gprotein).
Stimulated platelets from patients with the MS released more (P  0.05) sCD40L than controls
(582  141 vs. 334  60% change vs. nonstimulated platelets). AN reduced CD40L mRNA and
protein expression in monocytes from MS patients and endothelial cells.
Conclusions: The enhanced sCD40L and cellular CD40L expression in the MS suggests that CD40L
is of pathophysiological relevance in MS. Also, a new antiinflammatory effect of AN is described
through themodulation of the CD40/CD40L system. (J Clin EndocrinolMetab 93: 2319–2327, 2008)
The metabolic syndrome (MS) is characterized by a generalproinflammatory and prothrombotic state that interacts
synergistically causing or accelerating the progression of athero-
sclerosis (1, 2).
CD40 ligand (CD40L) and its receptor CD40 are expressed in
a wide variety of cells including vascular cells (3). There is in vitro
(4) and in vivo (5) evidence of the participation of CD40-CD40L
interactions in atherothrombosis. In addition to the cell-associ-
ated form, CD40L also exists in a circulating soluble form
(sCD40L). In humans, enhanced plasma sCD40L levels predict
primary (6) and secondary (7) cardiovascular (CV) events and
correlate with composition characteristics of the atheroma
plaque (8). Furthermore, sCD40L plasma levels associate with
other known CV risk factors, such as diabetes (9) and hyper-
cholesterolemia (10). In these two conditions, there is increased
expression of both the cell-associated and soluble form. MS is
also independently associated with elevated sCD40L (11–13).
However, surface CD40 and CD40L expression on circulating
cells of patients with MS and the possible sources that explain the
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overexpression of sCD40L in this syndrome have not been
explored.
Adipose tissue, in excess in the MS, releases bioactive mole-
cules named adipokines, such as adiponectin (AN) and others.
Reduced serum AN concentrations correlate with obesity, insu-
lin resistance, and type 2 diabetes (14). In addition to its meta-
bolic actions, AN also improves endothelial function and vas-
cular homeostasis by binding to its receptors, AdipoR1 and
AdipoR2, on monocytes, smooth muscle cells, and endothelial
cells (15–17). These cell types are involved at all stages of athero-
genesis and mediate inflammatory actions through the CD40/
CD40L dyad. However, the interplay between AN and CD40L
has not been explored.
Thus, we hypothesized that the CD40/CD40L system is up-
regulated in the MS and could be modulated by AN. The objec-
tives were: 1) to compare plasma and monocyte CD40L expres-
sion in patients with MS with controls and its association with
clinical and biochemical parameters, 2) to investigate platelets as
a source of circulating sCD40L levels in the MS, and 3) to analyze
the possible antiinflammatory effects of AN on the CD40/
CD40L system on monocytes and endothelial cells.
Subjects and Methods
Study population
The study was performed in 246 subjects without MS (73% men,
54 11 yr) and 128 patients with MS (91% men, 56 11 yr) attending
the Cardiovascular Risk Area of the University Clinic of Navarra for a
general check-up. Subjects were free from clinically apparent atheroscle-
rotic disease based on absence of history of coronary disease, stroke, or
peripheral artery disease and normal electrocardiogram. Exclusion cri-
teria were impaired renal or liver function, arteritis, and connective tissue
diseases. None of the subjects studied presented any inflammatory dis-
ease or condition associated with alterations in plasma sCD40L levels.
The local committee on human research approved the study, per-
formed in accordance with the Declaration of Helsinki, and all partici-
pants gave written informed consent.
All participants underwent a complete medical examination and an-
thropometric measurements. Blood pressure was measured using a mer-
cury sphygmomanometer. The average of two measurements was
considered.
MS was diagnosed according to the National Cholesterol Education
Program-Adult Treatment Panel III guidelines (18, 19) with modification
of waist criterion into body mass index (BMI;  30 kg/m2).
Clinical analyses
All subjects underwent ultrasonography of the common carotid ar-
teries performed with a 5- to 12-MHz linear-array transducer (ATL 500
HDI, Bothell, Washington). The measurement of intima-media thickness
(IMT) was made 1 cm proximal to the carotid bulb of each carotid artery
at plaque-free sites. From each individual, the IMT was determined as the
average of near- and far-wall measurements of each carotid artery. In
addition, the presence or absence of atheromatous plaques was
determined.
Biochemical analyses
Serum and plasma were collected in Vacutainer tubes. Fasting serum
glucose, cholesterol, triglycerides (TG), and high-density lipoprotein (HDL)
cholesterol were measured by standard laboratory techniques. Insulin levels
were determined by chemiluminescence in the Immulite 2000 (Diagnostic
Products Corp., Los Angeles, CA). Plasma levels of IL-12, IL-18, intercel-
lular adhesion molecule (ICAM)-1, vascular cell adhesion molecule
(VCAM)-1, and C-reactive protein (CRP) were measured by ELISA (R&D
Systems, Minneapolis, MN). Fibrinogen activity was determined by coag-
ulation assay (Dade Behring, Marburg, Germany).
The homeostasis model assessment (HOMA) of insulin resistance
TABLE 1. Demographics and clinical characteristics of the study population
Parameters
No. of factors of the MS
0 (n  59) 1–2 (n  187) 3–5 (n  128)
Aye (yr) 49  1 56  1 56  1
Gender (percent males) 51 82a 91a,b
BMI (kg/m2) 23  0.3 28  0.2a 30  0.3a,b
SBP (mm Hg) 115  2 128  1a 144  2a,b
DBP (mm Hg) 76  1 82  1a 88  1a,b
MAP (mm Hg) 89  1 97  1a 107  1a,b
Glucose (mg/dl) 92  1 99  1a 124  5a,b
HOMA of insulin resistance 2.1  0.85 3.6  1.82a 5.8  4.12a,b
TG (mg/dl) 69  3 104  4a 160  7a,b
HDL cholesterol (mg/dl) 65  1 52  1a 44  1a,b
LDL cholesterol (mg/dl) 149  4 155  3 160  3
Leptin (ng/ml) 9  2 7  1 7  1
ICAM-1 (ng/ml) 28  2 30  1 31  2
VCAM-1 (ng/ml) 1560  30 1689  25 1754  45a
IL-12 (ng/ml) 21  7 21  5 33  13a,b
IL-18 (ng/ml) 281  12 302  64 389  49a,b
CRP (ng/ml) 0.28  0.27 0.35  0.02 0.57  0.09a,b
Fibrinogen (mg/dl) 297  9 301  5 323  7a,b
Statin treatment (%) 0 11 15
Antihypertensive treatment (%) 0 18 29a,b
MAP, Mean arterial pressure; LDL, low-density lipoprotein.
a P  0.001 vs. group with no factors.
b P  0.001 vs. group with one to two factors.
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was calculated as insulin (microunits per milliliter) glucose (millimoles
per liter)/22.5.
sCD40L in serum and platelet supernatants or lysates (10 g) was
determined by ELISA (BenderMed Systems, Vienna, Austria), as previ-
ously described (9). The intraassay variation was less than 10%. AN
concentration was measured by ELISA (R&D Systems). Intraassay vari-
ation was less than 15%.
Reagents
RPMI 1640, penicillin/streptomycin mixture, fetal calf serum, PBS,
trypsin-EDTA, endothelial cell serum-free medium, and L-glutamine
were purchased from Life Technologies, Inc. (Paisley, UK). MEM199
and Hank’s balanced salt solution were purchased from BioWhittaker
(Verviers, Belgium) and collagenase A from Clostridium histolyticum
and protease inhibitors cocktail from Roche Molecular Biochemicals
(Mannheim, Germany). Recombinant TNF- and bovine gelatin were
purchased from Sigma (St. Louis, MO) and recombinant human adi-
ponectin/adipolean from PeproTech EC (London, UK).
Monocyte isolation and stimulation
For in vitro studies, cells from subjects with (three to five factors, n
20) or without MS (none to two factors, n  20) were collected to
increase the statistical power. Lymphomononuclear cells were obtained
from peripheral blood as described by Boyum (20). Cells were incubated
in RPMI 1640 medium with 10% heat-decomplemented fetal calf serum,
2 mmol/liter L-glutamine, 100U/ml penicillin, and 100 g/ml strepto-
mycin (37 C, 5% CO2). Human monocytes were isolated by adherence
to plastic surface. CD40/CD40L expression were determined by real-
time RT-PCR and Western blotting or ELISA.
To evaluate the effect of AN on the CD40/CD40L system, monocytes
from patients with MS (n 3) were cultured in the presence or absence
of recombinant human AN (30 g/ml) for 4 h (gene expression) or 24 h
(protein expression). As a control of the stimulation, levels of the pro-
and antiinflammatory cytokines (IL-6 and IL-10) were measured in cul-
ture supernatants by ELISA (R&D Systems).
Platelet isolation
Platelets were isolated from patients with the MS (n15) and healthy
controls (n 15) by layering citrated blood over a density barrier [Op-
tiprep (Fresenius; Oslo, Norway); 350 g, 15 min, 20 C]. The platelet-
containing band was resuspended in 140 mmol/liter NaCl, 3 mmol/liter
KCl, 0.5 mmol/liter MgCl2, 5 mmol/liter NaHCO3, 10 mmol/liter glu-
cose, 10 mmol/liter HEPES (pH 7.4). The concentration of platelets was
adjusted to 2  108/ml in the buffer and divided into two aliquots, and
purified platelets were allowed to rest. CD40L content in resting platelets
was measured by ELISA. Platelets in the second aliquot were stimulated
with thrombin (1 U/ml, 30 min, 37 C), supernatants obtained by cen-
trifugation (15 min, 1000  g), and sCD40L measured by ELISA.
Endothelial cells isolation and stimulation
Endothelial cells were isolated from human umbilical cords
(HUVECs) as described by Jaffe et al. (21) and incubated in MEM199
containing 20% human serum (37 C, 5% CO2) until confluence.
Twenty-four hours before stimulation, cultures were washed with
Hank’s balanced salt solution and fresh serum-free medium with anti-
biotics. Cultures were stimulated with AN (30 g/ml) in the presence of
a pretreatment with TNF- (50 ng/ml), a known inducer of CD40L
expression (22). Additional nonstimulated or stimulated with only
TNF- (50 ng/ml) cultures were maintained as negative and positive
controls, respectively. Gene (4 h) and protein (24 h) CD40/CD40L ex-
pression was determined by real-time RT-PCR and Western blotting. As
a control of the stimulation, levels of IL-6 and ICAM-1 were measured
in culture supernatants by ELISA.
Real-time RT-PCR
Total RNA was isolated from monocytes or endothelial cells using
Trizol (Invitrogen, Carlsbad, CA) and purified using RNeasy total RNA
isolation kit (QIAGEN, Valencia, CA). Reverse transcriptase was per-
formed with 250 ng total RNA. Real time RT-PCR was performed with
50 ng cDNA in an ABI PRISM7000 sequence detection system using
specific TaqMan MGB probes (Applied Biosystems, Foster City, CA).
Constitutive 18S ribosomal RNA was used as endogenous control.
For each experimental condition, the mean quantity of target gene
and endogenous control was obtained from a standard curve (represent-
ing cycle threshold values as the log amount of starting material) in
triplicate. The SD among triplicates was less than 0.2. The mean quantity
value of the target gene was divided by the mean value of the endogenous
control to obtain a normalized mean quantity per sample.
Western blotting
Monocytes or endothelial cell extracts were harvested in lysis buffer
[20 mmol/liter Tris (pH 8), 150 mmol/liter NaCl, 10% glycerol, 1%
Triton X-100, 2 mmol/liter EDTA, protease inhibitors cocktail] and
protein concentration assessed by the Bradford method (Bio-Rad, Her-
cules, CA). Fifteen micrograms of protein were fractionated on 12%
polyacrylamide gels and transferred into nitrocellulose membranes.
Membranes were blocked (5% nonfat dry milk in 0.05% Tween 20-PBS)
and incubated with a mouse monoclonal antihuman-CD40L (1:1000;
BenderMedSystems) or rabbit polyclonal antihuman CD40 (1:2000;
Santa Cruz Biotechnology, Santa Cruz, CA). Bound antibody was de-
tected by peroxidase-conjugated secondary antibody and visualized us-
ing the ECL-Plus chemiluminescence detection system (both Amersham
Biosciences, Piscataway, NJ).
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FIG. 1. sCD40L and adiponectin levels in patients with the MS. Patients
were divided into three groups according to the number of risk factors of
the MS and plasma concentrations of sCD40L and AN determined by
ELISA. A, Patients with more than three risk factors of the MS (n  128)
had higher circulating sCD40L levels than those with one or two (n  187)
or controls (n  59). B, AN levels decreased with the number of risk
factors, compared with controls. Bars represent mean sCD40L or AN
concentrations  SEM. n.s., Nonsignificant. *, P  0.05.
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Statistical analysis
The statistical analysis was performed with SPSS (version 13.0; SPSS, Chi-
cago, IL). The normal distribution of variables was tested with the Shapiro
Wilks test. Differences across groups were compared by ANOVA followed by
the Bonferroni post hoc test for normal variables and the Kruskal Wallis for
nonnormal variables. The unpaired Mann-Whitney U test was used to assess
statistical differences between experimental conditions. Spearman correlation
coefficients for continuous variables were also used to assess univariate corre-
lationsofsCD40LorANlevelswithallvariables.Multivariate linearregression
analysis was performed to assess the independent relationships between
sCD40Llevelsandothervariablesafteradjustingforotherconfoundingfactors.
Results are presented as mean SEM. P 0.05 was considered significant.
Results
Human studies
Demographicandclinicalcharacteristicsofthestudypopulation
To provide more detailed information, subjects were divided
into three groups according to the number of risk factors of the
MS (none, one to two, three to five). All parameters will be
compared with this classification in the following. Demographic
and clinical characteristics of the study population are presented
in Table 1. Patients with the MS had higher BMI, systolic blood
pressure (SBP), diastolic blood pressure (DBP), glucose, HOMA,
and TG levels than patients without the MS (one to two or no
factors, allP 0.001). HDL-C levels were lower in patients with
the MS, compared with the other two groups (both P 0.001).
Also, BMI, SBP, DBP, glucose, HOMA, and TG were higher and
HDL-C lower in patients with one to two factors, compared with
none.
We next characterized the proinflammatory profile of the
studied population. Patients with more than three risk factors
of the MS had higher (P  0.05) levels of IL-12, IL-18, CRP,
and fibrinogen than those with one to two and higher CRP and
fibrinogen than those with no factors (Table 1). Subjects with
three to five factors had higher VCAM-1 (P 0.05) levels than
subjects with none.
Plasma sCD40L and adiponectin levels in patients with MS
Interestingly, patients with more than three factors of the MS
had higher sCD40L levels than those with one to two or none
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FIG. 2. CD40 and CD40L expression in monocytes. Monocytes were obtained from healthy donors (n  20) and patients with the MS (n  20) by Ficoll
gradient and mRNA and protein isolated. CD40 and CD40L expression were determined by real-time RT-PCR (A) and Western blotting (CD40) or ELISA
(CD40L) (B). Bars represent mean SEM. *, P  0.05.
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(0.88 0.1 vs. 0.79 0.08 or 0.65 0.12 ng/ml; all P 0.05;
Fig. 1A). On the contrary, AN levels decreased with the number
of risk factors (no factors: 16.5 2.0 g/ml; one to two factors:
11.98  0.82 g/ml; three to five factors: 10.10  0.64 g/ml;
allP0.05; Fig. 1B). No significant linear association was found
between sCD40L and AN plasma concentrations.
In the entire population, no differences were found in
sCD40L levels between hypertensive and normotensive patients,
between patients with high and low TGs, or low and high HDL
cholesterol. In addition, no linear increase in sCD40L circulating
concentrations was found among nonobese, overweight, and
obese. However, diabetics had higher sCD40L levels than non-
diabetics (0.97  1.13 vs. 0.76  0.06 ng/ml, P  0.05). Inter-
estingly, the presence of the MS leads to higher sCD40L levels in
both the diabetic and nondiabetic groups (1.05  0.31 and
0.92  0.14 ng/ml, P  0.05), suggesting a synergistic effect of
risk factors.
We next explored the association of circulating sCD40L and
AN levels with other clinical and biochemical parameters. In the
whole population, after adjustment by age and gender, sCD40L
concentrations correlated with glucose, total cholesterol, CRP,
HOMA (all r 0.2,P 0.05) and IL-18 (r 0.3,P 0.05). AN
levels negatively correlated with HDL cholesterol and TG (r 
0.3 and r  0.4; P  0.05).
In patients with the MS, sCD40L levels correlated with IL-18
(r 0.2, P 0.05). In subjects with no factors of MS, sCD40L
levels correlated with IL-18 (r0.2,P0.05) and VCAM-1 (r
0.14, P  0.05), whereas AN levels associated with fibrinogen
(r  0.2, P  0.05).
No association was found between sCD40L concentrations
and carotid IMT. Also, sCD40L plasma concentrations did not
differ between patients with or without atheromatous plaques in
carotids (0.82  0.38 vs. 0.78  0.17 ng/ml).
CD40/CD40L system on circulating cells
Monocytes
CD40/CD40L expression were determined on circulating
monocytes by real-time RT-PCR for mRNA and Western blot-
ting (CD40) or ELISA (CD40L) for protein. Although we did not
find differences in CD40 mRNA expression, monocytes from
patients with MS expressed higher mRNA (P  0.05) of the
proinflammatory mediator CD40L (Fig. 2A) than those from
subjects without MS (CD40: 346  62 vs. 394  52 arbitrary
units; CD40L: 4.8  0.8 vs. 6.5  1.8 arbitrary units,). Both
CD40/CD40L protein expression, were significantly higher (P
0.05) in monocytes obtained from patients, compared with con-
trols (CD40: 1.31  0.31 vs. 0.80  0.14 arbitrary units;
CD40L: 1.24 0.85 vs. 0.43 0.14 pg/g of protein; Fig. 2B).
Platelets
More than 95% of the circulating sCD40L derives from plate-
lets as a result of activation by different agonists. Thus, to eval-
uate possible sources of sCD40L, we examined resting CD40L
content and sCD40L release from platelets isolated from patients
with MS and controls. No significant differences were observed
on CD40L intracellular content between resting platelets derived
from patients, compared with those from controls (7.7 3.5 vs.
7.2 2.2 pg/g of protein; Fig. 3A). Incubation with thrombin
induced sCD40L release from platelets, but interestingly, plate-
lets derived from patients with the MS released more (P 0.05)
sCD40L than those obtained from subjects without MS after
stimulation (582141 vs.33460% change vs.nonstimulated
platelets) (Fig. 3B).
Effects of adiponectin on vascular cells
Monocytes
Given that monocytes express receptors for AN, we next stud-
ied the effect of AN on the CD40/CD40L system in monocytes
from patients with the MS. CD40/CD40L expression deter-
mined by real-time PCR and Western blotting.
mRNA and protein expression of the receptor CD40 did not
significantly change after stimulation with AN, compared with
nontreated cells (mRNA: 358 87 vs. 524 21 arbitrary units;
protein: 0.6 0.1 vs. 0.8 0.2 arbitrary units; Fig. 4). By con-
trast, AN reduced (P 0.05) the mRNA and protein expression
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FIG. 3. Platelet CD40L content and release. A, Platelets were isolated
from healthy donors (n  15) and patients with the MS (n  15) and
CD40L content measured in duplicates by ELISA. Bars represent CD40L
content per microgram of total protein  SEM. B, Platelet sCD40L release
was measured in duplicate by ELISA after thrombin stimulation (1 U/ml, 30
min, 37 C). Bars represent mean percent of change, compared with
nonstimulated platelets  SEM. *, P  0.05 vs. thrombin-stimulated
platelets in patients without MS.
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of CD40L, compared with nonstimulated cells (mRNA: 3.6 
2.0 vs. 7.2 2.5 arbitrary units; protein: 0.8 0.2 vs. 1.9 0.8
arbitrary units)(Fig. 4).
The secretion of the proinflammatory cytokine IL-6 was in-
hibited (P  0.05) by AN, compared with nonstimulated cells
(10.04  1.53 vs. 12.03  1.3 pg/ml), whereas the secretion of
the antiinflammatory cytokine IL-10 was increased (P0.01) by
AN, compared with nonstimulated monocytes (645  235 vs.
16 5 ng/ml). AN also decreased the expression of the phospo-
nuclear factor-B, compared with the nonphosphorylated form
of this nuclear factor, further supporting that AN has an anti-
inflammatory effect on human monocytes (data not shown).
Endothelial cells
To test whether the antiinflammatory effect of AN extends to
other vascular cells, some experiments were performed in endo-
thelial cells. CD40/CD40L expression was induced in HUVECs
with TNF-, and cells were then incubated with AN.
Incubation with AN reduced (all P  0.05) TNF-induced
expression of CD40 and CD40L both at mRNA level (CD40:
187 18 vs. 383 137 arbitrary units; CD40L: 14.9 0.1 vs.
32.1  2.7 arbitrary units; Fig. 5A) and protein level (CD40:
0.93  0.03 vs. 1.53  0.01 arbitrary units;
CD40L: 0.44  0.13 vs. 3.0  0.04 arbitrary
units; Fig. 5B). AN alone had no effect on CD40
or CD40L expression in nonstimulated cells
(data not shown).
Finally, AN also inhibited (P  0.05) IL-6
(60.79  0.00 vs. 97.43  34.65 pg/ml) and
ICAM-1 (448  94 vs. 1910  779 ng/ml)
secretion.
Discussion
The main findings of the present study are: 1)
sCD40L levels are increased in patients with
MS, compared with controls; 2) circulating
monocytes of patients with MS express more
CD40 and CD40L than those from controls; 3)
platelets from patients with MS release more
sCD40L than those from controls after stimu-
lation; and 4) AN decreases CD40L expression
in monocytes and endothelial cells.
Up-regulation of the CD40/CD40L system
in the MS
The MS, with a prevalence of 25 confers in-
creased risk for CV events (1, 23). Inflamma-
tion is important precursor of the MS emerging
as a predictor of CV disease (24). Our study
confirms previous findings of elevated levels of
CRP and fibrinogen (25) and expands the char-
acterization of the inflammation in the MS to
other inflammatory cytokines and adhesion
molecules such as IL-12, IL-18, and VCAM-1.
But importantly, levels of the proinflammatory
mediator sCD40L increased with the number of risk factors.
Some authors have also described an independent association of
the MS with elevated sCD40L levels (11–13). However, it is
unknown whether enhanced levels could account for increased
incidence of CV events in this syndrome despite the fact that
several studies have shown that sCD40L can be used as a bi-
omarker for risk stratification (6, 7).
A novel finding of this study is that both CD40 and CD40L
protein expression were higher in monocytes from patients with
MS, compared with controls. The higher expression of the re-
ceptor CD40 in monocytes of patients with the MS indicates that
these cells are more susceptible to be activated by CD40L, either
in its soluble or cellular form. It is important to point out that the
sCD40L is similar to the membrane-bound form in terms of its
actions (26, 27). The interaction of the CD40L with its receptor
participates in different inflammatory responses, such as the in-
duction of proinflammatory cytokines, chemokines, matrix-de-
grading activities, and adhesion molecules on monocytes and
endothelial cells (22, 28). Thus, up-regulation of CD40 may rep-
resent a mechanism of amplification of CD40L-induced proin-
flammatory pathways and the up-regulation of the cellular
CD40L, an increased cell-cell interaction between atheroma-as-
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sociated cells. In other words, elevated expression of CD40 and
CD40L at sites of chronic inflammation could further contribute
to the inflammatory process of patients with the MS.
We next investigated the role of platelets as a source of
sCD40L in the MS. CD40L rapidly translocates to the platelet
surface after stimulation by thrombin, ADP, or collagen and then
is enzymatically cleaved generating the soluble fragment (4, 26).
We did not find differences in the intracellular CD40L content
between patients and controls, and a recent study did not find
differences in platelet CD40L surface expression between pa-
tients with and without MS (29). Taken together, these obser-
vations suggest that the increased sCD40L release from platelets
in patients with the MS is due to a higher activity of the enzyme
responsible of its processing.
After identifying the source of sCD40L, it is tempting to spec-
ulate about potential triggers of sCD40L release. Our study
shows that sCD40L plasma levels positively correlate with glu-
cose. Varo et al. (30) demonstrated elevated CD40L content and
inducible release from platelets of diabetic patients and identified
glucose and advanced glycation end products as triggers of re-
lease accounting for the elevated sCD40L levels in these patients.
High glucose is also associated with platelet activation and sur-
face CD40L expression (31). This effect of glucose on platelets
could account for the elevated sCD40L as-
sociated with glucose levels observed in pa-
tients with MS. However, of course, other
mediators involved in the MS could also trig-
ger sCD40L release.
Antiinflammatory effect of
adiponectin via CD40/CD40L
AN is a key metabolic regulator and
decreased levels confer increased risk for
CV disease (32). In addition to its insulin-
sensitizing properties, AN presents anti-
atherogenic effects by diminishing mono-
cyte adhesion to the endothelium,
decreasing smooth muscle cell prolifera-
tion, and reducing foam cell formation
(16, 17). Also, AN exerts antiinflamma-
tory effects on macrophages, suppressing
their production of proinflammatory cy-
tokines and inducing their production of
antiinflammatory cytokines (33, 34). Fi-
nally, physiological concentrations of AN
also inhibited TNF--induced monocyte
adhesion and expression of adhesion mol-
ecules on the endothelium (35).
These observations indicate that a rele-
vant interaction exists between the adipo-
cyte and vascular control mechanisms.
Given that the AN receptors are expressed
on macrophages and endothelials cells (36,
37), we hypothesized that this adipokine
could modulate the proinflammatory
CD40/CD40L dyad. Our results confirm
previous antiinflammatory effects of AN in
vascular cells (33) but, importantly, provide evidence that AN
down-regulates the CD40/CD40L system, in both macrophages
and endothelial cells. This study reports on what we believe is a
novel antiinflammatory and antiatherogenic mechanism of the
vascular protective action of AN. Because the molecular events
involved in CD40L down-regulation by AN in monocytes and
HUVECs remain to be fully elucidated, a detailed knowledge is
essential for the development of novel treatment strategies in
metabolic disorders.
Limitations and perspectives of the study
We used BMI to classify individuals in the current study be-
cause waist circumference measures were not available. Our
study confirms enhanced sCD40L levels in the MS, although we
failed to find any association between sCD40L levels and carotid
IMT in these patients or with the presence of atheromatous
plaques. There are contradictory data in the literature regarding
the association of circulating sCD40L levels and the presence of
subclinical atherosclerosis (38), but our results are in agreement
with those obtained by de Lemos et al. (39) in a large represen-
tative sample.
Future studies will be required to further evaluate which me-
diators of the MS are involved in the activation of both the cel-
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lular and soluble CD40L pathways. It has been suggested that
early regulation of plasma sCD40L levels by treatment of obesity
(40, 41) and diabetes (9) could result in lowering the risk of CV
disease. Direct pharmacologic manipulation of the axis CD40/
CD40L has also been tried with promising results in some cases
(42, 43). Future studies will be needed to further clarify whether
the ability of AN to directly modulate the CD40/CD40L system
may represent an important mechanistic basis of CV disease in
patients with the MS.
Summary
Our clinical and experimental study shows elevated circulat-
ing sCD40L levels, likely derived from activated platelets in pa-
tients with the MS. In addition to the soluble form, we show for
the first time that the monocyte CD40/CD40L system is also
up-regulated in patients with the MS, indicating that this dyad,
by amplifying and sustaining inflammation, may contribute to
CV risk in these patients. Also, we describe a new antiinflam-
matory effect of AN through the modulation of the CD40/
CD40L system, in both macrophages and endothelial cells, that
could be a novel mechanism through which AN may protect the
vasculature.
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